nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2019-6-4-62-68nodgo-555Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSНовые подходы в терапии солидных опухолей у детей и подростков с использованием таргетного препарата энтректинибNew approaches in the treatment of solid tumors in children and adolescents using the targeted drug entrectinibhttps://orcid.org/0000-0002-5489-1879СулеймановаА. М.SuleymanovaA. M.

Амина Магомедовна Сулейманова - врач-детский онколог.

115478, Москва, Каширское шоссе, 23

Pediatric Oncologist.

23 Kashirskoe Shosse, Moscow, 115478

a.sulejmanova@ronc.ruhttps://orcid.org/0000-0002-7846-3473СагоянГ. Б.SagoyanG. B.

Врач-детский онколог, SPIN-код: 6304-0159

115478, Москва, Каширское шоссе, 23

Pediatric Oncologist, SPIN-code: 6304-0159

23 Kashirskoe Shosse, Moscow, 115478

g.sagojan@ronc.ruhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovK. I.

Кандидат медицинских наук, заместитель директора по научной и образовательной работе.

115478, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work.

23 Kashirskoe Shosse, Moscow, 115478

k.kirgizov@ronc.ruНИИ детской онкологии и гематологии ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияResearch Institute of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian Federation201922012020646268Copyright © Сулейманова А.М., Сагоян Г.Б., Киргизов К.И., 20202020Сулейманова А.М., Сагоян Г.Б., Киргизов К.И.Suleymanova A.M., Sagoyan G.B., Kirgizov K.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/555

Гены рецепторной тирозинкиназы (NTRK1, 2, 3) являются протоонкогенами, которые встречаются при различных солидных опухолях у детей и взрослых. В настоящее время секвенирование нового поколения является предпочтительной платформой для обнаружения транслокаций гена NTRK. В научной литературе представлены данные об эффективности применения энтректи-ниба (entrectinib) у пациентов с транслокацией генов NTRK, ROS1 и ALK, независимо от гена-партнера. В перспективе терапия энтректинибом может стать альтернативой химиотерапии либо использоваться в комбинированном или комплексном лечении как первичных злокачественных новообразований, так и в случае рефрактерных, нерезектабельных и рецидивирующих форм заболевания.

The receptor tyrosine kinase genes (NTRK1, 2, 3) are proto-oncogenes that are found in various solid tumors in children and adults. Currently, next-generation sequencing (NGS) is the preferred platform for detecting NTRK gene translocations. The scientific literature presents data on the effectiveness of entrectinib in patients with translocation of the NTRK, ROS1 and ALK genes, regardless of the partner gene. In the future, entreсtinib therapy can become an alternative to chemotherapy or can be used in combination or complex treatment of both primary malignant neoplasms and in the case of refractory, unresectable and recurrent forms of the disease.

ген NTRKсолидные опухолидетивзрослыеингибиторы тирозинкиназыэнтректинибредкие опухолиNTRK gene fusionssolid tumorschildrenadulttyrosine kinase inhibitorentrectinibrare tumorsReferencesPenault-Llorca F., Rudzinski E.R., Sepulveda A.R. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 2019;72(7):460-7. doi: 10.1136/jclinpath-2018-205679.Penault-Llorca F., Rudzinski E.R., Sepulveda A.R. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 2019;72(7):460-7. doi: 10.1136/jclinpath-2018-205679.Amatu A., Sartore-Bianchi A., Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016;1(2):e000023. doi: 10.1136/esmoopen-2015-000023.Amatu A., Sartore-Bianchi A., Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016;1(2):e000023. doi: 10.1136/esmoopen-2015-000023.Pulciani S., Santos E., Lauver A.V., Long L.K., Aaronson S.A., Barbacid M. Oncogenes in solid human tumours. Nature 1982;300(5892):539-42. doi: 10.1038/300539a0.Pulciani S., Santos E., Lauver A.V., Long L.K., Aaronson S.A., Barbacid M. Oncogenes in solid human tumours. Nature 1982;300(5892):539-42. doi: 10.1038/300539a0.Weier H.U., Rhein A.P., Shadravan F., Collins C., Polikoff D. Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (fish), and computer-assisted microscopy. Genomics 1995;26:390-3. doi: 10.1016/0888-7543(95)80226-c.Weier H.U., Rhein A.P., Shadravan F., Collins C., Polikoff D. Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (fish), and computer-assisted microscopy. Genomics 1995;26:390-3. doi: 10.1016/0888-7543(95)80226-c.Nakagawara A., Liu X. G., Ikegaki N., White P.S., Yamashiro D.J., Nycum L.M., Biegel J.A., Brodeur G.M. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 1995;25:538-46. doi: 10.1016/0888-7543(95)80055-q.Nakagawara A., Liu X. G., Ikegaki N., White P.S., Yamashiro D.J., Nycum L.M., Biegel J.A., Brodeur G.M. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 1995;25:538-46. doi: 10.1016/0888-7543(95)80055-q.Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., Sivaramakrishnan S., O’Rahilly S., Farooqi I.S. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004;7:1187-9. doi: 10.1038/nn1336.Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., Sivaramakrishnan S., O’Rahilly S., Farooqi I.S. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004;7:1187-9. doi: 10.1038/nn1336.Cocco E., Scaltriti M., Drilon A. NTRK fusion-positive cancers and Trk inhibitor therapy. Nat Rev Clin Oncol 2018;15:731-47. doi: 10.1038/s41571-018-0113-0.Cocco E., Scaltriti M., Drilon A. NTRK fusion-positive cancers and Trk inhibitor therapy. Nat Rev Clin Oncol 2018;15:731-47. doi: 10.1038/s41571-018-0113-0.Vaishnavi A., Le A.T., Doebele R.C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5(1):25-34. doi: 10.1158/2159-8290.CD-14-0765.Vaishnavi A., Le A.T., Doebele R.C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5(1):25-34. doi: 10.1158/2159-8290.CD-14-0765.Stransky N., Cerami E., Schalm S., Kim J.L., Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846. doi: 10.1038/ncomms5846.Stransky N., Cerami E., Schalm S., Kim J.L., Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846. doi: 10.1038/ncomms5846.Chetty R. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes. J Clin Pathol 2019;72(3):187-90. doi: 10.1136/jclinpath-2018-205672.Chetty R. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes. J Clin Pathol 2019;72(3):187-90. doi: 10.1136/jclinpath-2018-205672.Hsiao S.J., Zehir A., Sireci A.N., Aisner D.L. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn 2019;21(4):553-71. doi: 10.m16/j.jmoldx.2019.03.008.Hsiao S.J., Zehir A., Sireci A.N., Aisner D.L. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn 2019;21(4):553-71. doi: 10.m16/j.jmoldx.2019.03.008.Solomon J.P., Hechtman J.F. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res 2019;79(13):3163-8. doi: 10.1158/0008-5472.CAN-19-0372.Solomon J.P., Hechtman J.F. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res 2019;79(13):3163-8. doi: 10.1158/0008-5472.CAN-19-0372.Gatalica Z., Xiu J., Swensen J., Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32(1):147-53. doi: 10.1038/s41379-018-0118-3.Gatalica Z., Xiu J., Swensen J., Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32(1):147-53. doi: 10.1038/s41379-018-0118-3.Hung Y.P., Fletcher C.D.M., Hornick J.L. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 2018;73(4):634-44. doi: 10.1111/his.13666.Hung Y.P., Fletcher C.D.M., Hornick J.L. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 2018;73(4):634-44. doi: 10.1111/his.13666.Chiang S., Cotzia P., Hyman D.M., Drilon A., Tap W.D., Zhang L., Hechtman J.F., Frosina D., Jungbluth A.A., Murali R., Park K.J., Soslow R.A., Oliva E., Iafrate A.J., Benayed R., Ladanyi M., Antonescu C.R. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Am J Surg Pathol 2018;42(6):791-8. doi: 10.1097/PAS.0000000000001055.Chiang S., Cotzia P., Hyman D.M., Drilon A., Tap W.D., Zhang L., Hechtman J.F., Frosina D., Jungbluth A.A., Murali R., Park K.J., Soslow R.A., Oliva E., Iafrate A.J., Benayed R., Ladanyi M., Antonescu C.R. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Am J Surg Pathol 2018;42(6):791-8. doi: 10.1097/PAS.0000000000001055.Hechtman J.F., Benayed R., Hyman D.M., Drilon A., Zehir A., Frosina D., Arcila M.E., Dogan S., Klimstra D.S., Ladanyi M., Jungbluth A.A. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol 2017;41(11):1547-51. doi: 10.m97/PAS.0000000000000911.Hechtman J.F., Benayed R., Hyman D.M., Drilon A., Zehir A., Frosina D., Arcila M.E., Dogan S., Klimstra D.S., Ladanyi M., Jungbluth A.A. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol 2017;41(11):1547-51. doi: 10.m97/PAS.0000000000000911.Roche. Japan becomes the first country to approve Roche’s personalized medicine Rozlytrek [media release]. 2019. https://www.roche.com/media/releases/med-cor-2019-06-18.htm.Roche. Japan becomes the first country to approve Roche’s personalized medicine Rozlytrek [media release]. 2019. https://www.roche.com/media/releases/med-cor-2019-06-18.htm.Drilon A., Siena S., Ou S.I., Patel M., Ahn M.J., Lee J., Bauer T.M., Farago A.F., Wheler J.J., Liu S.V., Doebele R., Giannetta L., Cerea G., Marrapese G., Schirru M., Amatu A., Bencardino K., Palmeri L., Sartore-Bianchi A., Vanzulli A., Cresta S., Damian S., Duca M., Ardini E., Li G., Christiansen J., Kowalski K., Johnson A.D., Patel R., Luo D., Chow-Maneval E., Hornby Z., Multani P.S., Shaw A.T., De Braud F.G. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017;7(4):400-9. doi: 10.1158/2159-8290.CD-16-1237.Drilon A., Siena S., Ou S.I., Patel M., Ahn M.J., Lee J., Bauer T.M., Farago A.F., Wheler J.J., Liu S.V., Doebele R., Giannetta L., Cerea G., Marrapese G., Schirru M., Amatu A., Bencardino K., Palmeri L., Sartore-Bianchi A., Vanzulli A., Cresta S., Damian S., Duca M., Ardini E., Li G., Christiansen J., Kowalski K., Johnson A.D., Patel R., Luo D., Chow-Maneval E., Hornby Z., Multani P.S., Shaw A.T., De Braud F.G. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017;7(4):400-9. doi: 10.1158/2159-8290.CD-16-1237.Doebele R.C., Drilon A., Paz-Ares L., Siena S., Shaw A.T., Farago A.F., Blakely C.M., Seto T., Cho B.C., Tosi D., Besse B., Chawla S.P., Bazhenova L., Krauss J.C., Chae Y.K., Barve M., Garrido-Laguna I., Liu S.V., Conkling P., John T., Fakih M., Sigal D., Loong H.H., Buchschacher G.L. Jr., Garrido P., Nieva J., Steuer C., Overbeck T.R., Bowles D.W., Fox E., Riehl T., Chow-Maneval E., Simmons B., Cui N., Johnson A., Eng S., Wilson T.R., Demetri G.D.; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2019;pii:S1470-2045(19)30691-6. doi: 10.1016/S1470-2045(19)30691-6.Doebele R.C., Drilon A., Paz-Ares L., Siena S., Shaw A.T., Farago A.F., Blakely C.M., Seto T., Cho B.C., Tosi D., Besse B., Chawla S.P., Bazhenova L., Krauss J.C., Chae Y.K., Barve M., Garrido-Laguna I., Liu S.V., Conkling P., John T., Fakih M., Sigal D., Loong H.H., Buchschacher G.L. Jr., Garrido P., Nieva J., Steuer C., Overbeck T.R., Bowles D.W., Fox E., Riehl T., Chow-Maneval E., Simmons B., Cui N., Johnson A., Eng S., Wilson T.R., Demetri G.D.; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2019;pii:S1470-2045(19)30691-6. doi: 10.1016/S1470-2045(19)30691-6.Robinson G.W., Gajjar A.J., Gauvain K.M., Basu E.M., Macy M.E., Maese L.D., Sabnis A.J., Foster J.H., Shusterman S., Yoon J., Weiss B.D., Abdelbaki M., Farid-Kapadia M., Meneses-Lorente G., Cardenas A., Hutchinson K., Bergthold G., Maneval E.C., Fox E., Desai A.V. Phase 1/1b trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. J Clin Oncol 2019;37(15 Suppl.):abstr. 10009. doi: 10.1200/JCO.2019.37.15_suppl.10009.Robinson G.W., Gajjar A.J., Gauvain K.M., Basu E.M., Macy M.E., Maese L.D., Sabnis A.J., Foster J.H., Shusterman S., Yoon J., Weiss B.D., Abdelbaki M., Farid-Kapadia M., Meneses-Lorente G., Cardenas A., Hutchinson K., Bergthold G., Maneval E.C., Fox E., Desai A.V. Phase 1/1b trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. J Clin Oncol 2019;37(15 Suppl.):abstr. 10009. doi: 10.1200/JCO.2019.37.15_suppl.10009.Desai A.V., Brodeur G.M., Foster J., Berg S.L., Basu E.M., Shusterman S., Sabnis A.J., Macy M., Yoon J., Gauvain K., Esquibel V., Maneval E.C., Multani P.S., Fox E. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. J Clin Oncol 2018;36(15 Suppl.):abstr. 10536. doi: 10.1200/JCO.2018.36.15_suppl.10536.Desai A.V., Brodeur G.M., Foster J., Berg S.L., Basu E.M., Shusterman S., Sabnis A.J., Macy M., Yoon J., Gauvain K., Esquibel V., Maneval E.C., Multani P.S., Fox E. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. J Clin Oncol 2018;36(15 Suppl.):abstr. 10536. doi: 10.1200/JCO.2018.36.15_suppl.10536.Al-Salama Z.T., Keam S.J. Entrectinib: First Global Approval. Drugs 2019;79(13):1477-83. doi: 10.1007/s40265-019-01177-y.Al-Salama Z.T., Keam S.J. Entrectinib: First Global Approval. Drugs 2019;79(13):1477-83. doi: 10.1007/s40265-019-01177-y.Doebele R., Ahn M., Siena S., Drilon A., Krebs M., Lin C., De Braud F., John T., Tan D., Seto T., Dziadziuszko R., Arkenau H., Barlesi F., Rolfo C., Wolf J., Chow-Maneval E., Multani P., Cui N., Riehl T., Cho B.C. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). J Thorac Oncol 2018;13(10 Suppl.):S321-S322;abstr. OA02.01 and presentation. doi: https://doi.org/10.1016/j.jtho.2018.08.239.Doebele R., Ahn M., Siena S., Drilon A., Krebs M., Lin C., De Braud F., John T., Tan D., Seto T., Dziadziuszko R., Arkenau H., Barlesi F., Rolfo C., Wolf J., Chow-Maneval E., Multani P., Cui N., Riehl T., Cho B.C. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). J Thorac Oncol 2018;13(10 Suppl.):S321-S322;abstr. OA02.01 and presentation. doi: https://doi.org/10.1016/j.jtho.2018.08.239.

The authors declare that there are no conflicts of interest present.